FAMD.F Stock Overview
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Futura Medical plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.42 |
| 52 Week High | UK£2.70 |
| 52 Week Low | UK£0.15 |
| Beta | 1.24 |
| 1 Month Change | -15.60% |
| 3 Month Change | 8.21% |
| 1 Year Change | -35.08% |
| 3 Year Change | -41.39% |
| 5 Year Change | 72.24% |
| Change since IPO | -60.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| FAMD.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.1% | -1.5% | -3.2% |
| 1Y | -35.1% | 9.7% | 19.3% |
Return vs Industry: FAMD.F underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: FAMD.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| FAMD.F volatility | |
|---|---|
| FAMD.F Average Weekly Movement | 29.1% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FAMD.F's share price has been volatile over the past 3 months.
Volatility Over Time: FAMD.F's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 12 | James Barder | www.futuramedical.com |
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel.
Futura Medical plc Fundamentals Summary
| FAMD.F fundamental statistics | |
|---|---|
| Market cap | US$132.57m |
| Earnings (TTM) | -US$8.05m |
| Revenue (TTM) | US$3.83m |
34.6x
P/S Ratio-16.5x
P/E RatioIs FAMD.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAMD.F income statement (TTM) | |
|---|---|
| Revenue | UK£3.10m |
| Cost of Revenue | UK£1.33m |
| Gross Profit | UK£1.77m |
| Other Expenses | UK£8.29m |
| Earnings | -UK£6.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 57.22% |
| Net Profit Margin | -210.03% |
| Debt/Equity Ratio | 0% |
How did FAMD.F perform over the long term?
See historical performance and comparison